{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:26:07Z","timestamp":1789025167037,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In this survey, we analyzed data from patients suffering from the most common cutaneous T\u2010cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and S\u00e9zary syndrome (SS), treated with the retinoid alitretinoin during a 7\u2010year period at our outpatient department between 2015 and 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 35 patients with MF (<jats:italic>n<\/jats:italic>\u00a0=\u00a028) and SS (<jats:italic>n<\/jats:italic>\u00a0=\u00a07) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56\u00a0\u00b1\u00a015\u00a0years in MF and 65.4\u00a0\u00b1\u00a010.8\u00a0years in SS with 51.4% having early stage (IA\u2013IIA) and 48.6% having advanced stage (IIB\u2013IVA) CTCL.<\/jats:p><jats:p>Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4237","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T06:59:32Z","timestamp":1629961172000},"page":"7071-7078","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Alitretinoin in the treatment of cutaneous T\u2010cell lymphoma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-2873","authenticated-orcid":false,"given":"Till","family":"Kaemmerer","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital LMU Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia\u2010Charlotte","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital LMU Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Helene Frommherz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital LMU Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Guertler","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital LMU Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Einar French","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital LMU Munich Germany"},{"name":"Dr. Phillip Frost Department of Dermatology &amp; Cutaneous Surgery Miller School of Medicine University of Miami Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reinholz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital LMU Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8829.1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18089"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00198"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa9122"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00300"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17073"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx352"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00116"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.007"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2008.07.002"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12413014"},{"issue":"5","key":"e_1_2_10_14_1","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T\u2010cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang C","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08931.x"},{"issue":"5","key":"e_1_2_10_16_1","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early\u2010stage cutaneous T\u2010cell lymphoma","volume":"137","author":"Duvic M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07329.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512484"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.05.011"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12684"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.73559"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124607"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14923"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1359"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021549"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13542"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:09:45Z","timestamp":1693339785000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":28,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/cam4.4237"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4237","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2021-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}